Avacta Share Discussion Threads

[cf456] 04/2/2019 11:32

finnCap increased target to 125p to reflect the incremental value of the deal.

---

"This therapeutic licence builds on the deal with LG Chem, ($300m “bio-dollars” plus royalties). It illustrates the clear progress that has been made underpinned by increasing amounts of preclinical data and therefore platform value, and is reflected in our increase in target price to 125p."

[cf456] 04/2/2019 11:25

Given that the current market cap is just over £50m, there's an awful lot of potential upside to a £1bn cap over time from here.

The CEO talks about the potential for "considerable valuation uplift" to "bring Avacta inline with comparators" in the near future.

The potential is certainly there. And 2019 looks to be an exciting one with scope for a number of deals to be announced.

[cf456] 04/2/2019 11:25

"Well done to the Avacta team that has worked closely with Moderna scientists over the past couple of years.

This licence agreement is another strong validation of the Affimer technology and allows Moderna to develop these Affimer molecules beyond our research collaboration and into the clinic."

[patientcapital] 04/2/2019 11:09

It could eventually be bigger than that. Moderna itself is a £4bn company. These are early days, of course, but it is looking like things are progressing in the right direction. finnCap’s target of 120p looks to have the potential of being upgraded as further collaborations are achieved.

[danatkins] 04/2/2019 10:51

This is a billion MC company in the making simply because if the tech is as great as they say then it will be sort after by many who need to develop new drugs/therapies

[cf456] 04/2/2019 10:42

No probs.

50k buy @ 50p from 9:08. £25k worth.

Someone confident in the upside.

[cheshire pete] 04/2/2019 10:29

The Drewster and cf456: Thanks for your clarifications. Yes I'd seen the statement in #2300 and it sounds very promising. The use of the word exclusive in the context of the RNS threw me a bit, unnecessarily as it turns out.

[cf456] 04/2/2019 10:01

"I suppose one has to be careful not to start getting hyperbolic, because what we have is a platform technology which means we are not a single asset drug company. There isn't one drug that we are developing. We have the ability to produce a very large pipeline of different Affimers because we have a platform to generate them from."

"So the potential value is genuinely enormous."

- from 7:54

[cf456] 04/2/2019 09:17

"With probably close to 50 companies that have or are undertaking evaluation we expect further licence deals to be announced in 2018 and onwards, all of which should generate incremental value." - finnCap

Any news that helps validate the Affimer technology is a positive and increases the chances of further deals being made in the near future.

[cf456] 04/2/2019 08:44

That's the beauty of the setup here.

The Affimer technology is a platform so the scope for doing deals relating to different Affimers is potentially enormous.

[the drewster] 04/2/2019 08:41

the exclusivity regards the specific affimers

[cheshire pete] 04/2/2019 08:32

So if another partner comes along, does that mean that the agreement is no longer exclusive? Some clarity would be welcome for thickies like me.

[toby hall] 04/2/2019 08:24

Good morning.
Chart is on the verge of a breakout.

[cf456] 04/2/2019 08:08

A positive RNS and yet further validation of Affimers which of course attracts potential new partners.

"This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development."

[nobbygnome] 04/2/2019 08:03

It is exclusive for certain targets which is quite normal! There are lots of other targets available to others....

[basem1] 04/2/2019 07:55

Does this prevent further larger deals with the word exclusivity being used.

[pugugly] 04/2/2019 07:30

Interesting and useful progress but no monetary details - all maybe depending on progress BUT no guide to value -

[the drewster] 04/2/2019 07:30

Moderna exercise exclusive options ... excellent news.

[cf456] 02/2/2019 08:01

And that's where the excitement is.

If the LG deal is the first of "several more" and "several major companies are nearing completion" then a number of significant deals could land in the short term.

Those selling now run the risk that they miss out on a news-drven surge in the share price.

Buy now and you expose yourself to a news-driven surge upwards in the short term and a much larger move over time as the story unfolds.

[myamay16] 01/2/2019 22:48

Taken from the Hardman & Co Q+A 12th Dec.(if on target should be news soon.)

Given that several major companies are nearing completion of the validation work for the Affimers, as I mentioned earlier, this deal with LG could be the first of several more and really act as a catalyst of more being done.

We expect that each subsequent deal is likely to be on better terms for Avacta so very important and it makes the valuation of the company look quite attractive.

[cf456] 01/2/2019 12:31

Quiet here at the moment.

But plenty of newsflow expected and an exciting 2019 to come according to the CEO.

Another deal like LG Chem could land at any time and put a rocket under the share price.

[hampton58] 30/1/2019 14:21

I would expect more news flow over the next couple of weeks as discussed post AGM.The Immuno Oncology sector is hottest sector in the Biotech sector, M&A activity, license/ Partnership deals being signed up.The Major Pharma need to put their cash pile to work, the return they are getting from their "traditional " products are not satisfactory.From a valuation perspective and read across , look at he following IPO being listed, the company is still involved in the " old" immuno therapy .Would be a continued buyer at these levelsImmuno-oncology biotech Harpoon Therapeutics sets terms for $76 million IPOJanuary 29, 2019HARPHarpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday.The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. Insiders intend to purchase $40 million worth of shares in the offering (53% of the deal). At the midpoint of the proposed range, Harpoon Therapeutics would command a fully diluted market value of $377 million. Harpoon Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol HARP. Citi and SVB Leerink are the joint bookrunners on the deal. It is expected to price during the week of February 4, 2019.

[cf456] 30/1/2019 14:13

Yes, the long game where the big profits are to be made in AVCT. The move since the LG Chem deal is just a taster of the much larger move that will unfold as time passes imo.

The recent AGM Business update statement gave some hints as to the likely newsflow in the coming months. There are multiple catalysts, each with the potential to drive the share price very much higher. The upwards momentum has only just started.

---

"I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company."

"As we expand those data-sets across our in-house programmes I am very confident that we will see additional significant licensing deals that transform the Company."

Tufts collaboration - "This is an exciting prospect that has got numerous large pharmaceutical partners interested in the Affimer TMACTM programme."

"The licensing deal with New England Biolabs is a perfect example of the type of deals we have in the pipeline of Affimer reagent evaluations and I expect that we will see more of these deals emerge in 2019 with both large and small partners across multiple markets."

[bumpa33] 30/1/2019 14:09

yep, was really referring to traders rather than those in it for the longer time frame.

[1i1i1i] 30/1/2019 14:02

Not boredom, just have to play the waiting game and enjoy the fruits of your research and investment. I'm feeling nice and content and good to see the price stable in a new range.